As such, the human LGMD2B myobundle model is expected to complement transgenic mice as a novel preclinical platform for mechanistic studies and therapeutic testing for dysferlinopathies. The gene discussed is DYSF; the disease is neuromuscular disease caused by qualitative or quantitative defects of dysferlin.